Tumour_NN Fas_NP ligand:Fas_NP ratio_NN greater_JJR than_IN 1_CD is_VBZ an_DT independent_JJ marker_NN of_IN relative_JJ resistance_NN to_TO tamoxifen_NP therapy_NN in_IN hormone_NN receptor_NN positive_JJ breast_NN cancer_NN Abstract_NP |_SYM Background_NN |_SYM The_DT objective_NN of_IN the_DT present_JJ study_NN was_VBD to_TO examine_VB the_DT prognostic_JJ and_CC predictive_JJ significance_NN of_IN the_DT apoptosis-related_JJ marker_NN Fas_NP ligand_NN (FasL):Fas_NNS ratio_NN in_IN breast_NN cancer_NN ._SENT Methods_NNS |_SYM Tumour_JJ biopsies_NNS from_IN 215_CD primary_JJ invasive_JJ breast_NN cancer_NN patients_NNS were_VBD examined_VBN for_IN the_DT expression_NN of_IN FasL_NP and_CC Fas_NP mRNA_NP transcripts_NNS by_IN quantitative_JJ real-time_JJ RT-PCR_NP ._SENT Their_PP$ prognostic_JJ and_CC predictive_JJ impact_NN on_IN patient_JJ survival_NN was_VBD determined_VBN in_IN univariate_JJ and_CC multivariate_JJ survival_NN analyses_NNS ._SENT Results_NNS |_SYM Using_VBG a_DT cutoff_NN value_NN of_IN 1_CD ,_, a_DT FasL:Fas_NP ratio_NN greater_JJR than_IN 1_CD was_VBD found_VBN to_TO have_VB significant_JJ prognostic_JJ value_NN for_IN disease-free_JJ survival_NN among_IN the_DT total_JJ population_NN (_( median_JJ follow_NN up_IN 54_CD months_NNS )_) ._SENT It_PP was_VBD associated_VBN with_IN a_DT significantly_RB decreased_VBN disease-free_JJ survival_NN (_( P_NN =_SYM 0.022_CD )_) and_CC with_IN a_DT tendency_NN toward_IN increased_VBN mortality_NN (_( P_NN =_SYM 0.14_CD )_) in_IN univariate_JJ analysis_NN ._SENT Hormone_NN receptor_NN positive_JJ women_NNS exclusively_RB treated_VBN with_IN tamoxifen_NP (_( n_NN =_SYM 86_CD )_) and_CC with_IN a_DT FasL:Fas_NP ratio_NN greater_JJR than_IN 1_CD had_VBD a_DT significantly_RB decreased_VBN disease-free_JJ survival_NN (_( P_NN =_SYM 0.008_CD )_) and_CC overall_JJ survival_NN (_( P_NN =_SYM 0.03_CD )_) in_IN univariate_JJ Kaplan_NP --_: Meier_NP analysis_NN ._SENT Furthermore_RB ,_, tumour_NN size_NN and_CC FasL:Fas_NP ratio_NN were_VBD of_IN independent_JJ predictive_JJ significance_NN in_IN the_DT multivariate_JJ model_NN for_IN disease-free_JJ and_CC overall_JJ survival_NN in_IN that_DT subgroup_NN ._SENT Among_IN postmenopausal_JJ patients_NNS (_( n_NN =_SYM 148_CD )_) both_CC of_IN those_DT factors_NNS retained_VBD independent_JJ prognostic_JJ significance_NN in_IN the_DT multivariate_JJ model_NN for_IN disease-free_JJ survival_NN ._SENT In_IN contrast_NN ,_, FasL:Fas_NP ratio_NN had_VBD no_DT significant_JJ predictive_JJ value_NN in_IN patients_NNS exclusively_RB treated_VBN with_IN chemotherapy_NN ._SENT Conclusion_NN |_SYM The_DT data_NNS presented_VBN indicate_VBP that_IN FasL:Fas_NP ratio_NN may_MD be_VB useful_JJ not_RB only_RB as_IN a_DT prognostic_JJ factor_NN but_CC also_RB as_IN a_DT predictive_JJ factor_NN for_IN projecting_VBG response_NN to_TO the_DT antioestrogen_NN tamoxifen_NN ._SENT The_DT results_NNS strongly_RB support_VBP a_DT correlation_NN between_IN FasL:Fas_NP ratio_NN greater_JJR than_IN 1_CD and_CC lack_NN of_IN efficacy_NN of_IN tamoxifen_NN in_IN hormone_NN receptor_NN positive_JJ patients_NNS ._SENT apoptosis_NN ,_, breast_NN cancer_NN ,_, Fas_NP ligand_NN ,_, predictive_JJ factor_NN ,_, tamoxifen_NP ,_, The_DT Fas_NP receptor_NN (_( CD95/APO-1_NP )_) is_VBZ a_DT widely_RB expressed_VBN glycosylated_JJ cell_NN surface_NN molecule_NN of_IN approximately_RB 45_CD --_: 52_CD kDa_NN ._SENT It_PP is_VBZ a_DT type_NN I_PP transmembrane_JJ receptor_NN and_CC can_MD also_RB occur_VB in_IN several_JJ soluble_JJ forms_NNS ._SENT Under_IN physiological_JJ conditions_NNS Fas-mediated_JJ apoptosis_NN is_VBZ triggered_VBN by_IN Fas_NP ligand_NN (_( FasL/CD95L_NP )_) ,_, the_DT natural_JJ ligand_NN of_IN the_DT receptor_NN ._SENT FasL_NP was_VBD shown_VBN to_TO be_VB a_DT tumour_NN necrosis_NN factor_NN related_JJ type_NN II_NP transmembrane_NN molecule_NN ,_, and_CC its_PP$ expression_NN is_VBZ more_RBR restricted_VBN than_IN that_DT of_IN Fas_NP ._SENT FasL_NP is_VBZ predominantly_RB detected_VBN in_IN activated_VBN T_NN cells_NNS and_CC activated_VBN natural_JJ killer_NN cells_NNS ,_, but_CC it_PP is_VBZ also_RB found_VBN on_IN some_DT macrophages/monocytes_NNS and_CC on_IN cells_NNS of_IN immune_JJ privileged_JJ tissues_NNS ._SENT Although_IN there_EX is_VBZ evidence_NN that_IN some_DT cancers_NNS express_VBP FasL_NP on_IN their_PP$ cell_NN surface_NN ,_, creating_VBG an_DT immune_JJ privileged_JJ site_NN ,_, a_DT number_NN of_IN laboratories_NNS have_VBP failed_VBN to_TO confirm_VB these_DT observations_NNS ._SENT These_DT findings_NNS ,_, in_IN addition_NN to_TO a_DT report_NN that_IN tumours_NNS transfected_VBN with_IN genes_NNS that_WDT express_VBP FasL_NP (_( which_WDT was_VBD originally_RB predicted_VBN to_TO accelerate_VB engraftment_NN )_) were_VBD unexpectedly_RB rejected_VBN ,_, have_VBP confounded_VBN interpretation_NN of_IN the_DT earlier_JJR studies_NNS and_CC the_DT role_NN of_IN FasL_NP in_IN immune_JJ recognition_NN of_IN malignancies_NNS ._SENT In_IN invasive_JJ breast_NN carcinomas_NNS the_DT expressions_NNS of_IN Fas_NP and_CC FasL_NP appeared_VBD to_TO be_VB inversely_RB related_VBN ._SENT A_DT significant_JJ association_NN was_VBD observed_VBN between_IN FasL_NP and_CC the_DT presence_NN of_IN metastatic_JJ lymph_NN nodes_NNS and_CC larger_JJR tumour_NN size_NN ,_, whereas_IN Fas_NP expression_NN was_VBD correlated_VBN with_IN node-negative_JJ status_NN and_CC smaller_JJR tumour_NN size_NN ._SENT Furthermore_RB ,_, high_JJ FasL_NP mRNA_NN and_CC protein_NN expression_NN appears_VBZ to_TO be_VB positively_RB correlated_VBN with_IN histological_JJ grading_VBG ,_, suggesting_VBG that_IN a_DT neoplastic_JJ Fas-negative/FasL-positive_JJ phenotype_NN may_MD be_VB linked_VBN to_TO breast_VB cancer_NN progression_NN ._SENT However_RB ,_, Ragnarsson_NP et_FW al._FW concluded_VBD that_IN FasL_NP is_VBZ expressed_VBN intracellularly_RB in_IN both_DT normal_JJ and_CC malignant_JJ breast_NN epithelium_NN and_CC is_VBZ unlikely_JJ to_TO be_VB important_JJ for_IN the_DT immune_JJ evasion_NN of_IN breast_NN tumours_NNS ._SENT We_PP previously_RB established_VBD the_DT FasL:Fas_NP ratio_NN in_IN tumour_NN tissue_NN as_IN a_DT prognostic_JJ factor_NN in_IN breast_NN carcinomas_NNS ._SENT An_DT extended_JJ follow_NN up_RB allows_VBZ a_DT re-evaluation_NN of_IN our_PP$ database_NN regarding_VBG the_DT prognostic_JJ and_CC predictive_JJ value_NN of_IN FasL:Fas_NP ratio_NN in_IN breast_NN carcinomas_NNS ._SENT In_IN particular_JJ ,_, we_PP investigated_VBD for_IN the_DT first_JJ time_NN whether_IN the_DT FasL:Fas_NP ratio_NN may_MD predict_VB response_NN to_TO cytotoxic_JJ or_CC hormonal_JJ therapies_NNS ,_, in_IN the_DT same_JJ way_NN that_IN the_DT presence_NN of_IN hormone_NN receptors_NNS predicts_VBZ response_NN to_TO hormonal_JJ treatment_NN ._SENT Using_VBG data_NNS obtained_VBN by_IN analysis_NN in_IN various_JJ subgroups_NNS ,_, the_DT findings_NNS presented_VBD here_RB contribute_VB to_TO the_DT recent_JJ controversial_JJ discussion_NN on_IN the_DT effects_NNS of_IN tumour-expressed_JJ FasL_NP in_IN vivo_RB ._SENT Patients_NNS and_CC tissue_NN collection_NN |_SYM Tissue_NP samples_NNS from_IN 215_CD unselected_JJ primary_JJ breast_NN carcinomas_NNS were_VBD collected_VBN during_IN surgery_NN at_IN the_DT Department_NP of_IN Obstetrics_NP and_CC Gynaecology_NP of_IN the_DT University_NP of_IN Rostock_NP between_IN 1994_CD and_CC 1998_CD ._SENT None_NN of_IN the_DT patients_NNS had_VBD received_VBN chemotherapy_NN ,_, radiotherapy_NN or_CC immunotherapy_NN before_IN surgery_NN ._SENT The_DT mean_JJ age_NN for_IN breast_NN cancer_NN patients_NNS was_VBD 58_CD years_NNS (_( range_NN 29_CD --_: 90_CD years_NNS )_) ._SENT The_DT majority_NN of_IN breast_NN tumours_NNS (_( n_NN =_SYM 199_CD [_SYM 92.5_CD %_NN ]_SYM )_) were_VBD invasive_JJ ductal_JJ carcinomas_NNS ._SENT The_DT median_JJ follow-up_NN time_NN was_VBD 54_CD months_NNS (_( range_NN 2_CD --_: 77_CD months_NNS )_) ._SENT The_DT main_JJ classifying_VBG prognostic_NN factors_NNS are_VBP shown_VBN in_IN Table_NP ._SENT A_DT total_NN of_IN 200_CD patients_NNS (_( 93_CD %_NN )_) received_VBD postoperative_JJ adjuvant_JJ therapy_NN ,_, consisting_VBG of_IN chemotherapy_NN (_( n_NN =_SYM 52_CD )_) ,_, hormone_NN therapy_NN (_( n_NN =_SYM 96_CD )_) ,_, or_CC both_DT (_( n_NN =_SYM 52_CD )_) ._SENT Among_IN patients_NNS undergoing_VBG endocrine_JJ treatment_NN 90_CD women_NNS (_( 93.7_CD %_NN )_) were_VBD treated_VBN with_IN tamoxifen_NP ,_, receiving_VBG an_DT oral_JJ dose_NN of_IN 20_CD mg/day_NN tamoxifen_NN for_IN a_DT maximum_NN of_IN 5_CD years_NNS ._SENT Among_IN the_DT tamoxifen-treated_JJ group_NN ,_, we_PP excluded_VBD four_CD patients_NNS with_IN hormone_NN receptor_NN negative_JJ tumours_NNS from_IN further_JJR survival_NN analysis_NN ._SENT Of_IN the_DT remaining_VBG 86_CD patients_NNS ,_, 41_CD blood_NN samples_NNS were_VBD available_JJ for_IN detection_NN of_IN serum_NN oestradiol_NN concentrations_NNS using_VBG the_DT SR1_JJ enzyme_NN immunoassay_NN (_( BioChem_NP Immunosystems_NP GmbH_NP ,_, Freiburg_NP ,_, Germany_NP )_) ._SENT Table_NP 1_CD |_SYM Clinicopathological_JJ characteristics_NNS of_IN 215_CD breast_NN cancer_NN patients_NNS and_CC univariate_JJ analysis_NN of_IN established_JJ prognostic_JJ factors_NNS for_IN disease-free_JJ and_CC overall_JJ survival_NN Real-time_JJ reverse_JJ transcription_NN polymerase_NN chain_NN reaction_NN |_SYM The_DT RT-PCR_NP procedure_NN and_CC preparation_NN of_IN RNA_NP standard_NN were_VBD described_VBN previously_RB ._SENT In_IN brief_JJ ,_, total_JJ RNA_NP of_IN freshly_RB frozen_VBN breast_NN tissue_NN was_VBD prepared_VBN in_IN accordance_NN with_IN the_DT acid_JJ guanidium_NN thiocyanate-phenol-chloroform_NN protocol_NN ._SENT All_DT specimens_NNS were_VBD tested_VBN by_IN analysis_NN of_IN glyceraldehyde-3-phosphate_NN dehydrogenase_NN housekeeping_NN gene_NN expression_NN using_VBG conventional_JJ RT-PCR_NP ._SENT First-trimester_NN placenta_NN (_( FasL_NP )_) from_IN women_NNS undergoing_VBG legal_JJ abortions_NNS and_CC liver_NN mRNA_NN (_( Fas_NP )_) served_VBD as_IN positive_JJ controls_NNS ._SENT The_DT primer_NN pairs_NNS and_CC probes_NNS were_VBD designed_VBN using_VBG the_DT Primer_NP ExpressTM_NP 1.0_CD program_NN (_( PE_NP Applied_NP Biosystems_NP ,_, Foster_NP City_NP ,_, CA_NP ,_, USA_NP )_) and_CC were_VBD obtained_VBN from_IN Applied_NP Biosystems_NP GmbH_NP (_( Weiterstadt_NP ,_, Germany_NP )_) ._SENT The_DT primers_NNS yielded_VBD RT-PCR_NP products_NNS of_IN 82_CD (_( FasL_NP )_) and_CC 105_CD (_( Fas_NP )_) nucleotides_NNS ._SENT For_IN calibration_NN of_IN the_DT FasL_NP and_CC Fas_NP TaqManTM_NP assays_NNS ,_, two_CD RNA_NP standards_NNS were_VBD generated_VBN using_VBG an_DT in_IN vitro_NP T7-polymerase_NP transcription_NN system_NN (_( RiboMAXTM_NP Large_NP Scale_NP RNA_NP Production_NP System_NP ;_: Promega_NP ,_, Madison_NP ,_, WI_NP ,_, USA_NP )_) ._SENT The_DT TaqMan_NP EZ_NP RT-PCR_NP Kit_NP (_( PE_NP Applied_NP Biosystems_NP )_) was_VBD used_VBN for_IN RT_NP and_CC amplification_NN of_IN both_DT targets_NNS and_CC standards_NNS ._SENT Production_NN of_IN cDNA_NP and_CC PCR_NP amplification_NN were_VBD carried_VBN out_RP in_IN a_DT single-tube_NN ,_, single-enzyme_NN system_NN ,_, without_IN addition_NN of_IN subsequent_JJ enzymes_NNS or_CC buffers_NNS ._SENT All_DT RT-PCR_NP reactions_NNS were_VBD performed_VBN in_IN duplicate_NN ,_, with_IN a_DT final_JJ volume_NN of_IN 25_CD mul_NN ._SENT Statistical_JJ analysis_NN |_SYM Clinical_JJ ,_, histological_JJ and_CC biological_JJ parameters_NNS were_VBD compared_VBN using_VBG the_DT most_RBS appropriate_JJ test_NN from_IN among_IN the_DT Spearman_NP correlation_NN coefficient_NN ,_, chi2_JJ test_NN ,_, Mann_NP --_: Whitney_NP U_NP test_NN and_CC Kruskal_NP --_: Wallis_NP H_NP test_NN ._SENT Disease-free_JJ and_CC overall_JJ survival_NN were_VBD analyzed_VBN using_VBG the_DT Kaplan_NP --_: Meier_NP method_NN ,_, and_CC comparison_NN of_IN study_NN groups_NNS was_VBD performed_VBN using_VBG the_DT log-rank_NN test_NN ._SENT The_DT Cox_NP regression_NN model_NN was_VBD applied_VBN over_IN both_DT univariate_JJ and_CC multivariate_JJ analyses_NNS ,_, with_IN the_DT associated_VBN likelihood_NN ratio_NN test_NN used_VBN for_IN tests_NNS of_IN trend_NN differences_NNS ._SENT In_IN multivariate_JJ analysis_NN ,_, a_DT backward_JJ stepwise_JJ selection_NN procedure_NN was_VBD used_VBN ._SENT The_DT Statistical_NP Package_NP for_IN Social_NP Science_NP (_( SPSS_NP Inc._NP ,_, Chicago_NP ,_, IL_NP ,_, USA_NP )_) was_VBD used_VBN to_TO conduct_VB statistical_JJ analysis_NN ._SENT In_IN all_DT tests_NNS P_NN <_SYM 0.05_CD was_VBD considered_VBN statistically_RB significant_JJ and_CC all_DT were_VBD two-tailed_JJ tests_NNS ._SENT Analysis_NN of_IN survival_NN among_IN the_DT total_JJ study_NN group_NN |_SYM The_DT impact_NN of_IN established_JJ prognostic_JJ parameters_NNS regarding_VBG disease-free_JJ and_CC overall_JJ survival_NN for_IN the_DT total_JJ population_NN is_VBZ listed_VBN in_IN Table_NP ._SENT Tumour_NN size_NN (_( P_NN =_SYM 0.001_CD )_) and_CC lymph_NN node_NN status_NN (_( P_NN =_SYM 0.009_CD )_) were_VBD significant_JJ factors_NNS for_IN disease-free_JJ survival_NN ,_, whereas_IN tumour_NN size_NN (_( P_NN <_SYM 0.001_CD )_) and_CC histological_JJ grading_VBG (_( P_NN =_SYM 0.003_CD )_) were_VBD significant_JJ prognostic_JJ parameters_NNS for_IN overall_JJ survival_NN within_IN univariate_JJ analysis_NN ._SENT Using_VBG the_DT cutoff_NN value_NN of_IN 1_CD ,_, a_DT FasL:Fas_NP ratio_NN greater_JJR than_IN 1_CD was_VBD found_VBN to_TO be_VB a_DT significant_JJ prognostic_JJ factor_NN for_IN disease-free_JJ survival_NN in_IN the_DT present_JJ update_NN analysis_NN ._SENT It_PP was_VBD associated_VBN with_IN a_DT significantly_RB decreased_VBN disease-free_JJ survival_NN (_( P_NN =_SYM 0.022_CD ;_: Fig._NN )_) and_CC with_IN a_DT tendency_NN toward_IN increased_VBN mortality_NN (_( P_NN =_SYM 0.14_CD ;_: Fig._NN )_) ._SENT The_DT mean_JJ disease-free_JJ survival_NN time_NN for_IN patients_NNS with_IN a_DT ratio_NN of_IN 1_CD or_CC less_JJR was_VBD 67_CD months_NNS (_( 95_CD %_NN confidence_NN interval_NN [_SYM CI_NP ]_SYM 63_CD --_: 70_CD months_NNS )_) versus_CC 59_CD months_NNS (_( 95_CD %_NN CI_NP 53_CD --_: 65_CD months_NNS )_) for_IN patients_NNS with_IN a_DT ratio_NN greater_JJR than_IN 1_CD ._SENT Figure_NP 1_CD |_SYM (_( a_DT )_) Disease-free_NP and_CC (_( b_LS )_) overall_JJ survival_NN curves_NNS for_IN breast_NN cancer_NN patients_NNS (_( n_NN =_SYM 211_CD )_) with_IN respect_NN to_TO Fas_NP ligand_NN (FasL):Fas_NNS ratio_NN ._SENT (_( a_DT )_) Disease-free_NP and_CC (_( b_LS )_) overall_JJ survival_NN curves_NNS for_IN breast_NN cancer_NN patients_NNS (_( n_NN =_SYM 211_CD )_) with_IN respect_NN to_TO Fas_NP ligand_NN (FasL):Fas_NNS ratio_NN ._SENT Survival_NN was_VBD analyzed_VBN using_VBG the_DT Kaplan_NP --_: Meier_NP method_NN ,_, and_CC comparison_NN of_IN study_NN groups_NNS was_VBD performed_VBN using_VBG the_DT log-rank_NN test_NN ._SENT All_DT variables_NNS that_WDT achieved_VBD significance_NN in_IN the_DT univariate_JJ survival_NN analysis_NN were_VBD incorporated_VBN in_IN a_DT multivariate_JJ analysis_NN ._SENT Tumour_NN size_NN (_( P_NN =_SYM 0.004_CD )_) and_CC lymph_NN node_NN status_NN (_( P_NN =_SYM 0.04_CD )_) were_VBD of_IN independent_JJ significance_NN in_IN the_DT multivariate_JJ disease-free_JJ survival_NN analysis_NN (_( n_NN =_SYM 208_CD )_) ._SENT Furthermore_RB ,_, tumour_NN size_NN (_( P_NN =_SYM 0.001_CD )_) and_CC grading_VBG (_( P_NN =_SYM 0.023_CD )_) were_VBD independent_JJ prognostic_JJ parameters_NNS for_IN overall_JJ survival_NN in_IN the_DT multivariate_JJ model_NN (_( n_NN =_SYM 208_CD )_) ._SENT Table_NP 2_CD |_SYM Multivariate_NP Cox_NP regression_NN analysis_NN for_IN disease-free_JJ and_CC overall_JJ survival_NN ,_, including_VBG prognostic_JJ factors_NNS that_WDT were_VBD significant_JJ on_IN univariate_JJ analysis_NN Analysis_NN of_IN survival_NN among_IN tamoxifen-treated_JJ patients_NNS |_SYM Ideally_RB ,_, a_DT predictive_JJ factor_NN should_MD be_VB evaluated_VBN only_RB in_IN the_DT setting_NN of_IN individuals_NNS who_WP have_VBP not_RB received_VBN different_JJ systemic_JJ therapies_NNS ._SENT For_IN this_DT reason_NN we_PP divided_VBD the_DT total_JJ population_NN into_IN hormone_NN receptor_NN positive_JJ tamoxifen-treated_NN (_( n_NN =_SYM 86_CD )_) and_CC chemotherapy-treated_JJ (_( n_NN =_SYM 52_CD )_) subgroups_NNS ._SENT Among_IN the_DT tamoxifen-treated_JJ subgroup_NN 75_CD patients_NNS (_( 83.3_CD %_NN )_) were_VBD node_NN negative_JJ ._SENT The_DT FasL:Fas_NP ratio_NN values_NNS were_VBD positively_RB correlated_VBN with_IN histological_JJ grading_VBG (_( P_NN =_SYM 0.048_CD )_) and_CC serum_NN oestradiol_NN concentrations_NNS (_( P_NN =_SYM 0.04_CD )_) ._SENT Women_NNS with_IN a_DT FasL:Fas_NP ratio_NN greater_JJR than_IN 1_CD had_VBD significantly_RB higher_JJR serum_NN oestradiol_NN levels_NNS than_IN did_VBD women_NNS with_IN a_DT FasL:Fas_NP ratio_NN of_IN 1_CD or_CC less_JJR (_( P_NN =_SYM 0.002_CD )_) ._SENT No_DT associations_NNS between_IN FasL:Fas_NP ratio_NN and_CC other_JJ factors_NNS such_JJ as_IN tumour_NN size_NN (_( P_NN =_SYM 0.129_CD )_) ,_, lymph_NN node_NN status_NN (_( P_NN =_SYM 0.378_CD )_) ,_, age_NN (_( P_NN =_SYM 0.822_CD )_) ,_, body_NN mass_NN index_NN (_( P_NN =_SYM 0.174_CD )_) and_CC use_VB of_IN exogenous_JJ hormones_NNS (_( P_NN =_SYM 0.732_CD )_) were_VBD observed_VBN ._SENT Women_NNS exclusively_RB treated_VBN with_IN tamoxifen_NP (_( n_NN =_SYM 86_CD )_) and_CC with_IN a_DT FasL:Fas_NP ratio_NN greater_JJR than_IN 1_CD had_VBD a_DT significantly_RB decreased_VBN disease-free_JJ survival_NN (_( P_NN =_SYM 0.0084_CD )_) and_CC overall_JJ survival_NN (_( P_NN =_SYM 0.03_CD )_) on_IN univariate_JJ Kaplan_NP --_: Meier_NP analysis_NN ._SENT The_DT mean_JJ disease-free_JJ survival_NN time_NN for_IN tamoxifen-treated_JJ patients_NNS with_IN a_DT ratio_NN of_IN 1_CD or_CC less_JJR was_VBD 71_CD months_NNS (_( 95_CD %_NN CI_NP 67_CD --_: 75_CD months_NNS )_) versus_CC 57_CD months_NNS (_( 95_CD %_NN CI_NP 48_CD --_: 67_CD months_NNS )_) for_IN patients_NNS with_IN a_DT ratio_NN greater_JJR than_IN 1_CD ._SENT The_DT corresponding_JJ data_NNS for_IN overall_JJ survival_NN were_VBD 74_CD months_NNS (_( 95_CD %_NN CI_NP 70_CD --_: 77_CD months_NNS )_) for_IN a_DT ratio_NN of_IN 1_CD or_CC less_JJR and_CC 66_CD months_NNS (_( 95_CD %_NN CI_NP 58_CD --_: 73_CD months_NNS )_) for_IN a_DT ratio_NN greater_JJR than_IN 1_CD ._SENT Tumour_NN size_NN (_( P_NN =_SYM 0.013_CD )_) and_CC FasL:Fas_NP ratio_NN (_( P_NN =_SYM 0.013_CD )_) were_VBD significantly_RB related_VBN to_TO reduced_VBN disease-free_JJ survival_NN in_IN univariate_JJ Cox_NP regression_NN analysis_NN ._SENT Tumour_NN size_NN (_( P_NN =_SYM 0.023_CD )_) and_CC FasL:Fas_NP ratio_NN (_( P_NN =_SYM 0.027_CD )_) were_VBD also_RB of_IN independent_JJ prognostic_JJ significance_NN in_IN the_DT multivariate_JJ model_NN (_( n_NN =_SYM 86_CD )_) ._SENT The_DT relative_JJ risk_NN for_IN occurrence_NN of_IN breast_NN cancer_NN related_JJ relapse_NN in_IN tamoxifen-treated_JJ patients_NNS was_VBD 3.0_CD (_( 95_CD %_NN CI_NP 1.14_CD --_: 7.9_CD )_) for_IN women_NNS with_IN a_DT FasL:Fas_NP ratio_NN greater_JJR than_IN 1_CD ._SENT Figure_NP 2_CD |_SYM (_( a_DT )_) Disease-free_NP and_CC (_( b_LS )_) overall_JJ survival_NN curves_NNS for_IN tamoxifen-treated_JJ ,_, hormone_NN receptor_NN positive_JJ breast_NN cancer_NN patients_NNS (_( n_NN =_SYM 86_CD )_) with_IN respect_NN to_TO Fas_NP ligand_NN (FasL):Fas_NNS ratio_NN ._SENT (_( a_DT )_) Disease-free_NP and_CC (_( b_LS )_) overall_JJ survival_NN curves_NNS for_IN tamoxifen-treated_JJ ,_, hormone_NN receptor_NN positive_JJ breast_NN cancer_NN patients_NNS (_( n_NN =_SYM 86_CD )_) with_IN respect_NN to_TO Fas_NP ligand_NN (FasL):Fas_NNS ratio_NN ._SENT Survival_NN was_VBD analyzed_VBN using_VBG the_DT Kaplan_NP --_: Meier_NP method_NN ,_, and_CC comparison_NN of_IN study_NN groups_NNS was_VBD performed_VBN using_VBG the_DT log-rank_NN test_NN ._SENT Table_NP 3_CD |_SYM Cox_NP regression_NN analysis_NN for_IN disease-free_JJ and_CC overall_JJ survival_NN in_IN tamoxifen-treated_JJ ,_, hormone_NN receptor_NN positive_JJ patients_NNS Corresponding_VBG analyses_NNS for_IN overall_JJ survival_NN in_IN tamoxifen-treated_JJ patients_NNS revealed_VBD prognostic_JJ impact_NN of_IN tumour_NN size_NN (_( P_NN =_SYM 0.002_CD )_) ,_, tumour_NN grading_VBG (_( P_NN =_SYM 0.015_CD )_) and_CC FasL:Fas_NP ratio_NN (_( P_NN =_SYM 0.042_CD )_) in_IN the_DT univariate_JJ setting_NN ._SENT The_DT multivariate_JJ analysis_NN confirmed_VBD all_DT three_CD of_IN those_DT parameters_NNS as_IN independent_JJ markers_NNS for_IN overall_JJ survival_NN in_IN tamoxifen-treated_JJ patients_NNS ._SENT Analysis_NN of_IN survival_NN among_IN postmenopausal_JJ patients_NNS |_SYM The_DT tamoxifen-treated_JJ subgroup_NN (_( age_NN range_NN 50_CD --_: 90_CD years_NNS )_) comprised_VBD 94.5_CD %_NN postmenopausal_NN and_CC 5.5_CD %_NN premenopausal_JJ patients_NNS ,_, and_CC we_PP therefore_RB re-analyzed_JJ the_DT data_NNS for_IN the_DT postmenopausal_JJ population_NN (_( n_NN =_SYM 149_CD )_) ._SENT On_IN univariate_JJ Kaplan_NP --_: Meier_NP analysis_NN ,_, postmenopausal_JJ women_NNS with_IN a_DT FasL:Fas_NP ratio_NN greater_JJR than_IN 1_CD had_VBD decreased_VBN disease-free_JJ survival_NN (_( P_NN =_SYM 0.01_CD )_) and_CC overall_JJ survival_NN (_( P_NN =_SYM 0.182_CD )_) as_IN compared_VBN with_IN postmenopausal_JJ women_NNS with_IN a_DT ratio_NN of_IN 1_CD or_CC less_JJR ._SENT The_DT mean_JJ disease-free_JJ survival_NN time_NN for_IN postmenopausal_JJ patients_NNS with_IN a_DT ratio_NN of_IN 1_CD or_CC less_JJR was_VBD 67_CD months_NNS (_( 95_CD %_NN CI_NP 62_CD --_: 71_CD months_NNS )_) versus_CC 56_CD months_NNS (_( 95_CD %_NN CI_NP 49_CD --_: 63_CD months_NNS )_) for_IN patients_NNS with_IN a_DT ratio_NN greater_JJR than_IN 1_CD ._SENT The_DT corresponding_JJ data_NNS for_IN overall_JJ survival_NN were_VBD 69_CD months_NNS (_( 95_CD %_NN CI_NP 65_CD --_: 73_CD months_NNS )_) and_CC 65_CD months_NNS (_( 95_CD %_NN CI_NP 59_CD --_: 71_CD months_NNS )_) ,_, respectively_RB ._SENT Tumour_NN size_NN (_( P_NN =_SYM 0.001_CD )_) and_CC FasL:Fas_NP ratio_NN (_( P_NN =_SYM 0.01_CD )_) were_VBD significantly_RB related_VBN to_TO reduced_VBN disease-free_JJ survival_NN on_IN univariate_JJ Cox_NP regression_NN analysis_NN ._SENT Figure_NP 3_CD |_SYM (_( a_DT )_) Disease-free_NP and_CC (_( b_LS )_) overall_JJ survival_NN curves_NNS for_IN postmenopausal_JJ breast_NN cancer_NN patients_NNS (_( n_NN =_SYM 149_CD )_) with_IN respect_NN to_TO Fas_NP ligand_NN (FasL):Fas_NNS ratio_NN ._SENT (_( a_DT )_) Disease-free_NP and_CC (_( b_LS )_) overall_JJ survival_NN curves_NNS for_IN postmenopausal_JJ breast_NN cancer_NN patients_NNS (_( n_NN =_SYM 149_CD )_) with_IN respect_NN to_TO Fas_NP ligand_NN (FasL):Fas_NNS ratio_NN ._SENT Survival_NN was_VBD analyzed_VBN using_VBG the_DT Kaplan_NP --_: Meier_NP method_NN ,_, and_CC comparison_NN of_IN study_NN groups_NNS was_VBD performed_VBN using_VBG the_DT log-rank_NN test_NN ._SENT Table_NP 4_CD |_SYM Cox_NP regression_NN analysis_NN for_IN disease-free_JJ and_CC overall_JJ survival_NN in_IN postmenopausal_JJ patients_NNS Both_CC factors_NNS (_( tumour_NN size_NN P_NN =_SYM 0.003_CD ;_: FasL:Fas_NP ratio_NN P_NN =_SYM 0.028_CD )_) retained_VBD independent_JJ prognostic_JJ significance_NN in_IN the_DT multivariate_JJ model_NN (_( n_NN =_SYM 148_CD )_) ._SENT The_DT relative_JJ risk_NN for_IN occurrence_NN of_IN breast_NN cancer_NN related_JJ relapse_NN in_IN postmenopausal_JJ patients_NNS was_VBD 2.04_CD (_( 95_CD %_NN CI_NP 1.14_CD --_: 7.36_CD )_) for_IN women_NNS with_IN a_DT ratio_NN greater_JJR than_IN 1_CD ._SENT Among_IN the_DT postmenopausal_JJ subgroup_NN no_DT associations_NNS between_IN FasL:Fas_NP ratio_NN and_CC other_JJ factors_NNS such_JJ as_IN tumour_NN size_NN (_( P_NN =_SYM 0.096_CD )_) ,_, tumour_NN grading_VBG (_( P_NN =_SYM 0.108_CD )_) ,_, lymph_NN node_NN status_NN (_( P_NN =_SYM 0.339_CD )_) ,_, age_NN (_( P_NN =_SYM 0.55_CD )_) ,_, oestrogen_NN receptor_NN (_( ER_NP ;_: P_NN =_SYM 0.741_CD )_) ,_, progesterone_NN receptor_NN (_( P_NN =_SYM 0.748_CD )_) ,_, body_NN mass_NN index_NN (_( P_NN =_SYM 0.92_CD )_) and_CC use_VB of_IN exogenous_JJ hormones_NNS (_( P_NN =_SYM 0.26_CD )_) were_VBD observed_VBN ._SENT Analysis_NN of_IN survival_NN among_IN patients_NNS undergoing_VBG cytotoxic_JJ therapy_NN |_SYM In_IN contrast_NN to_TO the_DT findings_NNS summarized_VBD above_RB ,_, FasL:Fas_NP ratio_NN had_VBD no_DT significant_JJ prognostic_JJ value_NN in_IN patients_NNS treated_VBN exclusively_RB with_IN chemotherapy_NN ._SENT Using_VBG Kaplan_NP --_: Meier_NP analysis_NN ,_, disease-free_JJ (_( P_NN =_SYM 0.94_CD )_) and_CC overall_JJ survival_NN (_( P_NN =_SYM 0.765_CD )_) were_VBD not_RB related_VBN to_TO FasL:Fas_NP ratio_NN ._SENT Similarly_RB ,_, no_DT significant_JJ associations_NNS were_VBD found_VBN between_IN FasL:Fas_NP ratio_NN and_CC survival_NN time_NN in_IN premenopausal_JJ patients_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT Recurrence_NN pattern_NN |_SYM Because_IN of_IN the_DT significance_NN of_IN FasL:Fas_NP ratio_NN for_IN disease-free_JJ survival_NN in_IN postmenopausal_JJ or_CC tamoxifen-treated_JJ women_NNS ,_, we_PP analyzed_VBD the_DT pattern_NN of_IN locoregional_JJ and_CC distant_JJ relapse_NN ._SENT Among_IN the_DT 149_CD postmenopausal_JJ patients_NNS ,_, 39_CD (_( 26.2_CD %_NN )_) had_VBD recurrent_JJ disease_NN ._SENT The_DT relapse_NN rate_NN was_VBD 39.3_CD %_NN (_( n_NN =_SYM 22_CD )_) in_IN 56_CD patients_NNS with_IN a_DT ratio_NN greater_JJR than_IN 1_CD and_CC 18.3_CD %_NN (_( n_NN =_SYM 17_CD )_) in_IN 93_CD women_NNS with_IN a_DT ratio_NN of_IN 1_CD or_CC less_JJR ._SENT Skeletal_JJ (_( 41.2_CD %_NN )_) and_CC pulmonary_JJ metastases_NNS (_( 23.5_CD %_NN )_) ,_, and_CC locoregional_JJ progression_NN (_( 23.5_CD %_NN )_) were_VBD frequently_RB observed_VBN in_IN postmenopausal_JJ patients_NNS with_IN a_DT ratio_NN of_IN 1_CD or_CC less_JJR ._SENT Liver_JJR (_( 33.3_CD %_NN )_) and_CC skeletal_JJ metastases_NNS (_( 22.2_CD %_NN )_) ,_, and_CC locoregional_JJ progression_NN (_( 22.2_CD %_NN )_) occurred_VBD predominantly_RB in_IN patients_NNS with_IN a_DT ratio_NN greater_JJR than_IN 1_CD ._SENT However_RB ,_, no_DT specific_JJ recurrence_NN patterns_NNS were_VBD detected_VBN with_IN respect_NN to_TO FasL:Fas_NP ratio_NN ._SENT At_IN present_NN there_EX are_VBP only_RB two_CD factors_NNS with_IN clinical_JJ level_NN 1_CD evidence_NN supporting_VBG a_DT predictive_JJ role_NN for_IN response_NN to_TO breast_VB cancer_NN therapy_NN ._SENT First_RB ,_, optimal_JJ adjuvant_JJ hormonal_JJ therapy_NN is_VBZ 5_CD years_NNS of_IN tamoxifen_NN for_IN anyone_NN with_IN a_DT tumour_NN that_WDT is_VBZ hormone_NN receptor_NN positive_JJ ,_, even_RB if_IN at_IN a_DT low_JJ level_NN ._SENT Patients_NNS whose_WP$ cancers_NNS express_VBP neither_DT ER_NN nor_CC progesterone_NN receptor_NN will_MD not_RB be_VB helped_VBN by_IN tamoxifen_NP administration_NN ._SENT Second_JJ ,_, recent_JJ data_NNS suggest_VBP that_IN adjuvant_JJ treatment_NN with_IN trastuzumab_NN will_MD prove_VB ineffective_JJ for_IN tumours_NNS with_IN low_JJ levels_NNS of_IN HER-2/neu_NP expression_NN ._SENT The_DT new_JJ data_NNS presented_VBD here_RB indicate_VB that_IN the_DT FasL:Fas_NP ratio_NN may_MD be_VB useful_JJ not_RB only_RB as_IN a_DT prognostic_JJ factor_NN but_CC also_RB as_IN a_DT predictive_JJ factor_NN for_IN projecting_VBG response_NN to_TO the_DT antioestrogen_NN tamoxifen_NN ._SENT In_IN patients_NNS with_IN hormone_NN receptor_NN positive_JJ primary_JJ tumours_NNS ,_, a_DT FasL:Fas_NP ratio_NN greater_JJR than_IN 1_CD defines_VBZ a_DT subgroup_NN of_IN patients_NNS who_WP are_VBP less_RBR likely_JJ to_TO respond_VB to_TO tamoxifen_NP ._SENT Women_NNS exclusively_RB treated_VBN with_IN tamoxifen_NP and_CC with_IN a_DT FasL:Fas_NP ratio_NN greater_JJR than_IN 1_CD had_VBD a_DT 14-month_JJ shorter_JJR mean_JJ disease-free_JJ survival_NN and_CC a_DT relative_JJ risk_NN of_IN 3.0_CD for_IN relapse_NN of_IN disease_NN as_IN compared_VBN with_IN patients_NNS with_IN a_DT FasL:Fas_NP ratio_NN of_IN 1_CD or_CC less_JJR ._SENT Furthermore_RB ,_, a_DT ratio_NN greater_JJR than_IN 1_CD was_VBD associated_VBN with_IN a_DT significantly_RB shorter_JJR overall_JJ survival_NN (_( P_NN =_SYM 0.043_CD )_) and_CC a_DT relative_JJ risk_NN for_IN death_NN of_IN 3.65_CD in_IN that_DT subgroup_NN ._SENT No_DT correlation_NN was_VBD seen_VBN between_IN FasL:Fas_NP ratio_NN and_CC survival_NN time_NN in_IN patients_NNS receiving_VBG cytotoxic_JJ treatment_NN ._SENT The_DT unexpected_JJ finding_NN that_IN FasL:Fas_NP ratio_NN is_VBZ a_DT prognostic_JJ factor_NN in_IN postmenopausal_NN and_CC a_DT predictive_JJ factor_NN in_IN tamoxifen-treated_JJ patients_NNS may_MD be_VB accounted_VBN for_IN by_IN hormone_NN dependency_NN ._SENT Various_JJ studies_NNS suggest_VBP that_IN the_DT FasL/Fas_NP system_NN may_MD play_VB an_DT important_JJ role_NN in_IN the_DT regulation_NN of_IN cell_NN death_NN in_IN response_NN to_TO hormonal_JJ changes_NNS ._SENT Nilsen_NP et_FW al._FW showed_VBD that_IN oestrogen_NN induces_VBZ apoptosis_NN in_IN neurone-like_JJ cells_NNS that_WDT express_VBP ER-beta_NP ,_, and_CC that_IN this_DT is_VBZ mediated_VBN by_IN the_DT FasL/Fas_NP system_NN ._SENT Selam_NP et_FW al._FW suggested_VBD that_IN oestradiol_NN and_CC progesterone_NN may_MD play_VB a_DT role_NN in_IN regulating_VBG maternal_JJ immunotolerance_NN for_IN the_DT implantation_NN of_IN a_DT semiallograft_NN embryo_NN by_IN inducing_VBG FasL_NP expression_NN in_IN human_JJ endometrium_NN ._SENT Recent_JJ findings_NNS support_VBP the_DT hypothesis_NN that_IN oestrogen-induced_JJ thymic_JJ atrophy_NN occurs_VBZ as_IN a_DT result_NN of_IN apoptosis_NN and_CC is_VBZ mediated_VBN by_IN oestrogen-induced_JJ FasL_NP expression_NN ._SENT Finally_RB ,_, maintenance_NN of_IN endothelial_JJ FasL_NP expression_NN by_IN oestradiol_NN may_MD represent_VB a_DT mechanism_NN for_IN the_DT apparently_RB antiatherogenic_JJ effect_NN of_IN oestrogen_NN ._SENT Novel_NN findings_NNS further_RBR link_VB the_DT FasL/Fas_NP system_NN and_CC hormones_NNS such_JJ as_IN oestrogen_NN and_CC lactogenic_JJ hormones_NNS to_TO the_DT biology_NN of_IN the_DT normal_JJ mammary_JJ gland_NN and_CC the_DT development_NN of_IN breast_NN cancer_NN ._SENT Treatment_NN of_IN LTED_JJ cells_NNS ,_, which_WDT were_VBD derived_VBN by_IN growing_VBG MCF-7_JJ breast_NN cancer_NN cells_NNS under_IN long-term_JJ oestrogen-deprived_JJ conditions_NNS ,_, with_IN oestradiol_NN increased_VBD the_DT expression_NN of_IN FasL_NP ._SENT Mor_NP et_FW al._FW showed_VBD that_IN FasL_NP in_IN breast_NN tissue_NN is_VBZ functionally_RB active_JJ ,_, and_CC that_DT oestrogen_NN and_CC tamoxifen_NN regulate_VB its_PP$ expression_NN ._SENT Those_DT investigators_NNS identified_VBD an_DT oestrogen-recognizing_JJ element-like_JJ motif_NN in_IN the_DT promoter_NN region_NN of_IN the_DT FasL_NP gene_NN ,_, suggesting_VBG direct_JJ effects_NNS of_IN oestrogen_NN on_IN FasL_NP expression_NN ._SENT This_DT effect_NN is_VBZ receptor_NN mediated_VBN because_IN tamoxifen_NP blocked_VBD the_DT oestrogenic_JJ effect_NN ._SENT The_DT indication_NN for_IN use_NN of_IN antioestrogens_NNS in_IN mammary_JJ carcinoma_NN arises_VBZ from_IN the_DT observations_NNS that_IN oestrogen_NN is_VBZ a_DT mitogen_NN in_IN breast_NN cancer_NN and_CC that_IN approximately_RB one-third_JJ of_IN patients_NNS will_MD respond_VB to_TO endocrine_JJ therapy_NN ._SENT The_DT main_JJ therapeutic_JJ antioestrogen_NN that_WDT has_VBZ been_VBN used_VBN is_VBZ tamoxifen_NP ._SENT The_DT present_JJ data_NNS indicate_VBP that_IN the_DT antitumour_NN effect_NN of_IN tamoxifen_NP varies_VBZ according_VBG to_TO the_DT FasL:Fas_NP ratio_NN of_IN the_DT breast_NN tumour_NN ,_, and_CC values_NNS of_IN the_DT ratio_NN are_VBP positively_RB correlated_VBN to_TO serum_NN oestradiol_NN levels_NNS ._SENT The_DT use_NN of_IN tamoxifen_NN in_IN patients_NNS with_IN a_DT FasL:Fas_NP ratio_NN greater_JJR than_IN 1_CD is_VBZ less_RBR effective_JJ than_IN in_IN those_DT with_IN higher_JJR ratios_NNS ,_, leading_VBG to_TO the_DT hypothesis_NN that_IN the_DT recently_RB developed_VBN aromatase_NN inhibitors_NNS anastrozole_NN ,_, letrozole_NN and_CC exemestan_NN are_VBP more_RBR appropriate_JJ in_IN these_DT patients_NNS ,_, or_CC that_IN additional_JJ cytotoxic_JJ treatment_NN will_MD be_VB of_IN benefit_NN in_IN this_DT subgroup_NN ._SENT The_DT role_NN of_IN FasL_NP expressed_VBD by_IN breast_NN tumour_NN in_IN the_DT induction_NN of_IN apoptosis_NN of_IN infiltrating_VBG Fas-expressing_NP immune_JJ cells_NNS ,_, and_CC thereby_RB conferring_VBG immune_JJ privilege_NN on_IN the_DT tumour_NN ,_, is_VBZ at_IN present_JJ unclear_JJ ._SENT The_DT expression_NN of_IN FasL_NP by_IN tumours_NNS implies_VBZ not_RB only_RB that_IN cancers_NNS have_VBP acquired_VBN defensive_JJ strategies_NNS (_( Fas_NP resistance_NN )_) but_CC also_RB that_IN they_PP can_MD take_VB the_DT offensive_JJ (_( counterattack_NN )_) ._SENT On_IN the_DT basis_NN of_IN the_DT findings_NNS presented_VBD here_RB ,_, we_PP hypothesize_VBP that_IN the_DT association_NN between_IN high-FasL/low-Fas_NNS phenotype_NN and_CC shorter_JJR disease-free_JJ survival_NN in_IN older_JJR breast_NN carcinoma_NN patients_NNS may_MD be_VB due_JJ to_TO a_DT decline_NN in_IN immune_JJ function_NN ,_, which_WDT results_VBZ in_IN increased_VBN escape_NN of_IN tumour_NN cells_NNS from_IN immune_JJ surveillance_NN ._SENT Of_IN special_JJ interest_NN are_VBP age-related_JJ changes_NNS in_IN tumour-infiltrating_VBG lymphocytes_NNS ._SENT Cytotoxic_JJ lymphocytes_NNS from_IN aged_VBN mice_NNS are_VBP less_RBR able_JJ to_TO bind_NN targets_NNS ,_, although_IN they_PP appear_VBP to_TO be_VB equally_RB effective_JJ in_IN destroying_VBG their_PP$ targets_NNS ._SENT Assuming_VBG that_DT FasL-positive_JJ tumour_NN cells_NNS interact_VBP with_IN tumour-infiltrating_VBG lymphocytes_NNS ,_, our_PP$ clinical_JJ data_NNS support_VBP indirectly_RB the_DT counterattack_NN model_NN ._SENT Immune_JJ surveillance_NN among_IN older_JJR patients_NNS is_VBZ insufficient_JJ in_IN breast_NN carcinomas_NNS with_IN a_DT FasL:Fas_NP ratio_NN greater_JJR than_IN 1_CD ,_, which_WDT leads_VBZ to_TO an_DT increased_VBN rate_NN of_IN locoregional_JJ or_CC distant_JJ metastases_NNS and_CC to_TO a_DT shorter_JJR disease-free_JJ survival_NN in_IN postmenopausal_JJ patients_NNS ._SENT However_RB ,_, there_EX is_VBZ little_JJ evidence_NN to_TO support_VB direct_JJ causal_JJ links_NNS between_IN immune_JJ senescence_NN and_CC most_JJS malignancies_NNS ,_, although_IN data_NNS from_IN in_IN vitro_NN and_CC in_IN vivo_JJ animal_NN and_CC human_JJ studies_NNS demonstrate_VBP clear_JJ age-related_JJ alterations_NNS in_IN both_DT cellular_JJ and_CC humoral_JJ components_NNS of_IN the_DT immune_JJ system_NN ._SENT The_DT present_JJ findings_NNS confirm_VBP the_DT prognostic_JJ significance_NN of_IN FasL:Fas_NP ratio_NN in_IN breast_NN carcinoma_NN in_IN a_DT re-evaluated_NN database_NN over_IN 54_CD months_NNS of_IN follow_VB up_RP ._SENT Particularly_RB in_IN postmenopausal_JJ patients_NNS ,_, the_DT FasL:Fas_NP ratio_NN retained_VBD independent_JJ prognostic_JJ significance_NN in_IN multivariate_JJ analysis_NN for_IN disease-free_JJ survival_NN ._SENT Additionally_RB ,_, the_DT data_NNS strongly_RB support_VBP a_DT correlation_NN between_IN FasL:Fas_NP ratio_NN greater_JJR than_IN 1_CD and_CC lack_NN of_IN efficacy_NN of_IN tamoxifen_NN in_IN hormone_NN receptor_NN positive_JJ patients_NNS ._SENT However_RB ,_, given_VBN the_DT important_JJ therapeutic_JJ repercussions_NNS of_IN this_DT issue_NN ,_, further_JJR studies_NNS are_VBP required_VBN before_IN evaluation_NN of_IN FasL:Fas_NP ratio_NN can_MD be_VB routinely_RB used_VBN to_TO select_VB patients_NNS who_WP are_VBP likely_JJ to_TO benefit_VB from_IN tamoxifen_NN administration_NN ._SENT CI_NN =_SYM confidence_NN interval_NN ;_: ER_NP =_SYM oestrogen_NN receptor_NN ;_: FasL_NP =_SYM Fas_NP ligand_NN ;_: PCR_NP =_SYM polymerase_NN chain_NN reaction_NN ;_: RT_NP =_SYM reverse_JJ transcription_NN ._SENT 